Safety of alternative treatments for menopausal symptoms after breast cancer: A qualitative systematic review

Climacteric

Volumn 10, Issue 1, 2007, Pages 23-26

  Antoine, C ^a   Liebens, F ^a   Carly, B ^a   Pastijn, A ^a   Rozenberg, S ^a  

^a SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Antidepressive agents; Black cohosh; Breast cancer survivors; Clonidine; Gabapentin; Phytoestrogens; Tibolone; Veralipride

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; CIMICIFUGA RACEMOSA EXTRACT; CLONIDINE; PHYTOESTROGEN; SEROTONIN UPTAKE INHIBITOR; TIBOLONE; VERALIPRIDE;

ALTERNATIVE MEDICINE; BREAST CANCER; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; DRUG SAFETY; HUMAN; MENOPAUSAL SYNDROME; PRIORITY JOURNAL; REVIEW;

ANTIDEPRESSIVE AGENTS; BREAST NEOPLASMS; ESTROGEN RECEPTOR MODULATORS; FEMALE; HISTAMINE H1 ANTAGONISTS; HOT FLASHES; HUMANS; MENOPAUSE; NORPREGNENES;

EID: 33847091089     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.1080/13697130601176734     Document Type: Review

References (24)

1. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide, Version 1. 0IARC CancerBase No. 5. Lyon: IARC Press, 2001
2. American Cancer Society (ACS). Cancer Statistics Presentation, 2004
3. Berry DA, Cronin KA, Plevritis SK, et al. for the Cancer Intervention and Surveillance Modeling Network (CISNET) Collaborators. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005;353:1784-92
4. Goodwin PJ, Ennis M, Pritchard KI, Trudeau M, Hood N. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol 1999;17:2365-70
5. Lower EE, Blau R, Gazder P, Tummala R. The risk of premature menopause induced by chemotherapy for early breast cancer. J Womens Health Gend Based Med 1999;8:949-54
6. Harris PF, Remington PL, Trentham-Dietz A, Allen CI, Newcomb PA. Prevalence and treatment of menopausal symptoms among breast cancer survivors. J Pain Symptom Manage 2002;23:501-9
7. Cobleigh MA, Berris RF, Bush T, et al. Estrogen replacement therapy in breast cancer survivors. A time for change. Breast Cancer Committees of the Eastern Cooperative Oncology Group. JAMA 1994;272:540-5
8. Brzezinski A. Management of menopause in women with breast cancer. Isr J Med Sci 1995;31:163-8
9. Trinh XB, Van Hal G, Weyler J, Tjalma WA. The thoughts of physicians regarding the need to start hormone replacement therapy in breast cancer survivors. Eur J Obstet Gynecol Reprod Biol 2006;124:207-11
10. Hoda D, Perez DG, Loprinzi CL. Hot flashes in breast cancer survivors. Breast J 2003;9:431-8
11. Hickey M, Saunders CM, Stuckey BG. Management of menopausal symptoms in patients with breast cancer: an evidence-based approach. Lancet Oncol 2005;6:687-95
12. Antoine C, Liebens F, Carly B, Pastijn A, Neusy S, Rozenberg S. Safety of hormone therapy after breast cancer: a qualitative systematic review. Hum Reprod 2006 Oct 18; Epub ahead of print
13. Ginsburg J, Prelevic GM. Tibolone in postmenopausal women with a history of breast carcinoma. J Br Menopause Soc 1995 October:24-5
14. O'Brien M, Montes A, Powles TJ. Hormone replacement therapy as treatment of breast cancer - a phase II study of Org OD 14 (tibilone). Br J Cancer 1996;73:1086-8
15. Weiss SR, McFarland BH, Burkhart GA, Ho PT. Cancer recurrences and secondary primary cancers after use of antihistamines or antidepressants. Clin Pharmacol Ther 1998;63:594-9
16. Kroiss R, Fentiman IS, Helmond FA, et al. The effect of tibolone in postmenopausal women receiving tamoxifen after surgery for breast cancer: a randomised, double-blind, placebo-controlled trial. Br J Obstet Gynaecol 2005;112:228-33
17. Dimitrakakis C, Keramopoulos D, Vourli G, Gaki V, Bredakis N, Keramopoulos A. Clinical effects of tibolone in postmenopausal women after 5 years of tamoxifen therapy for breast cancer. Climacteric 2005;8:342-51
18. Nikander E, Kilkkinen A, Metsa-Heikkila M, et al. A randomized placebo-controlled crossover trial with phytoestrogens in treatment of menopause in breast cancer patients. Obstet Gynecol 2003;101:1213-20
19. Debourdeau P, Bachelot T, Zammit C, Aletti M, Gallineau C, Gligorov J. Treatment of hot flashes in women with a previous diagnosis of breast cancer. Bull Cancer 2004;91:339-49
20. Pandya KJ, Morrow GR, Roscoe JA, et al. Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. Lancet 2005;366:818-24
21. Reddy SY, Warner H, Guttuso T Jr, et al. Gabapentin, estrogen, and placebo for treating hot flushes: a randomized controlled trial. Obstet Gynecol 2006;108:41-8
22. Lawlor DA, Juni P, Ebrahim S, Egger M. Systematic review of the epidemiologic and trial evidence of an association between antidepressant medication and breast cancer. J Clin Epidemiol 2003;56:155-63
23. Bonin B, Vandel S. Drug interactions and new antidepressive agents. Therapie 1995;50:229-36
24. Stearns V, Johnson MD, Rae JM, et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 2003;95:1758-64